The Link Between Insomnia and Mental Illness
By: Gogi Francis
The Link Between Insomnia and Mental Illness
Insomnia and mental illness are both on the rise. Treatment can help.
Posted May 19, 2021 | By: Jennifer Reid M.D.
- Mental Illness and insomnia are highly interconnected, with the incidence of psychiatric illness in patients with insomnia near 50%.
- Cognitive-behavioral therapy for insomnia (CBT-I) is safe and effective. Studies suggest benefits persist long-term.
- Providers are of CBT-I are few. Digital, self-guided versions of CBT-I can help to bridge this gap.
Insomnia rates have continued to rise throughout the pandemic, contributing to increasing rates of depression and anxiety, as well as worsening symptoms of other severe mental illnesses. Defined as chronic sleep onset and/or sleep continuity problems associated with impaired daytime functioning, insomnia has a bidirectional relationship with mental health issues.
Mental Illness and Insomnia: How Do They Interact?
The incidence of psychiatric illness in patients with insomnia is estimated to be near 50 percent. The highest comorbidity rates have been noted in mood disorders, including depression and bipolar disorder, as well as anxiety disorders. In patients with diagnosed major depressive disorder, as many as 90 percent struggle with insomnia.
Insomnia has also been identified as a risk factor for the development of a mental illness. In a meta-analysis of patients with insomnia published in 2011, the authors concluded that persistent insomnia can more than double the risk of major depression.
Another 2019 meta-analysis of more than 130,000 participants assessed the effects of baseline insomnia on the development of a psychiatric illness over a five-year period. Individuals with insomnia demonstrated a significantly higher risk of alcohol abuse and psychosis. Additionally, insomnia tripled the likelihood of being diagnosed with a depressive or anxiety disorder.
Sleep disturbances can also worsen symptoms of diagnosed mental illness, including substance abuse, mood, and psychotic disorders. Laskemoen and colleagues found that a startling 74 percent of participants with diagnoses of schizophrenia or bipolar spectrum had at least one type of sleep disturbance (insomnia, hypersomnia, or delayed sleep phase)—nearly twice the rates in healthy controls. Importantly, compared to those with mental illness not suffering from sleep disturbances, sleep-disordered participants had more severe negative and depressive symptoms on the positive and negative syndrome scale (PANSS), as well as significantly lower function as measured by global assessment of functioning (GAF).
How Can Insomnia Be Treated?
Although insomnia symptoms can resolve after relief from a particular life stressor, as many as 50 percent of patients with more severe symptoms will have a chronic course. Many of the sedative-hypnotics are designed for short-term use, though are frequently continued beyond the recommended time frame. In a survey reviewing the national use of prescription drugs for insomnia, as many as 20 percent of individuals use a medication to target insomnia in a given month.
The benefits of cognitive-behavioral therapy for insomnia (CBT-I) have been demonstrated repeatedly, and it is recommended as the first-line treatment for insomnia by the Clinical Guidelines of the American Academy of Sleep Medicine, Center for Disease Control , and the National Institute of Health . Studies suggest benefits persist long-term, even after completing the therapy sessions have ended.
One study also suggested that tapering a sedative-hypnotic (Zolpidem in this case) after combined treatment with six weeks of CBT-I leads to better long-term results (up to two years in the study) compared to continued medication use on an as-needed basis. Importantly, CBT-I also has demonstrated benefit in patients with psychiatric comorbidities.
A shortage of providers trained in CBT-I significantly limits the availability of this effective treatment option. For example, a recent review noted that 58 percent of the 659 behavioral sleep medicine (BSM) providers in the United States reside in just 12 states. Also, more than 100 U.S. cities with populations larger than 150,000 are without BSM providers. Contrast this with the estimated 9 to 15 percent of the population suffering from insomnia (likely a conservative estimate in light of the pandemic). Additionally, higher unemployment rates add further importance to the estimated excess employer cost of $2,000/year per employee with insomnia, compared to their well-rested counterparts.
Digital, self-guided versions of CBT-I can help to bridge this gap. However, the growing numbers of individuals suffering from chronic insomnia in combination with other mental health issues suggest investment is needed to bolster our delivery of this effective treatment. Support on a massive scale is needed to correct this provider shortage, which is a highly costly and significant risk to our nation’s public health.
Voitsidis P, Gliatas I, Bairachtari V, et al. Insomnia during the COVID-19 pandemic in a Greek population. Psychiatry Res. 2020;289:113076.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing, 2013.
Ford DE, Kamerow DB. Epidemiological study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA. 1989;262:1479-84
Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res. 2003;37:9-15.
Seow LSE, Subramaniam M, Abdin E, et al. Sleep disturbance among people with major depressive disorders (MDD) in Singapore. J Mental Health 2016;25(6):1-8.
Thase ME. Antidepressant treatment of the depressed patient with insomnia. J Clin Psych. 1999;60(17):28-31; discussion 46-28.
Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135:10-19.
Hertenstein E, Feige B, Gmeiner T, et al. Insomnia as a predictor of mental disorders: A systematic review and meta-analysis. Sleep Medicine Rev. 2019;43:96-105.
Brower KJ et al. Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances. Medical Hypotheses. 2010;74(5):928-33.
Laskemoen JF, Simonsen C, Büchmann C, et al. Sleep disturbances in schizophrenia spectrum and bipolar disorders—a transdiagnostic perspective. Comprehensive Psychiatry. 2019;91:6-12.
Morin CM, Belanger L, LeBlanc M, et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med. 2009;169:447-53.
Cheung J, Xiao-Wen J, Morin C. Cognitive behavioral therapies for insomnia and hypnotic medications: considerations and controversies. Sleep Med Clin. 2019;14:253-265.
Bertisch SM, Herzig SJ, Winkelman JW et al., National use of prescription medications for insomnia: NHANES 1999-2010. Sleep. 2014 Feb 1;37(2):343-9.
Okajima I, Komada Y, Inoue Y. A meta-analysis on the treatment effectiveness of cognitive behavioral therapy for primary insomnia. Sleep Biol Rhythms. 2011;9:24e34.
Trauer JM, Qian MY, Doyle JS, Rajaratnam SW, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:191e204.
Edinger J, Arnedt JT, Bertisch S, et al., Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 2021;17(2):255-262.
Beaulieu-Bonneau S, Ivers H, Guay B, and Morin CM. Long-term maintenance of therapeutic gains associated with cognitive-behavioral therapy for insomnia delivered alone or combined with zolpidem. SLEEP 2017;40(3):zsx002. doi: 10.1093/sleep/zsx002
Wu JQ, Appleman ER, Salazar RD, Ong JC. Cognitive behavioral therapy for insomnia comorbid with psychiatric and medical conditions: a meta-analysis. JAMA Intern Med. 2015;175(9):1461–72.
Thomas A, Grandner M, Nowakowski S, et al. Where are the behavioral sleep medicine providers and where are they needed? A geographic assessment. Behav Sleep Med. 2016;14(6):687–698. doi: 10.1080/15402002.2016.1173551
Ohayon, M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Medicine Reviews. 2002;6(2):97-111.
Kleinman NL, Brook RA, Doan JF, et al. Health benefit costs and absenteeism dur to insomnia from the employer’s perspective: a retrospective, case-control, database study. J Clin Psychiatry. 2009;70(8):1098-1104.
Luik AI, Kyle SD, Espie CA. Digital Cognitive Behavioral Therapy (dCBT) for Insomnia: a State-of-the-Science Review. Curr Sleep Med Rep. 2017;3(2):48-56. doi: 10.1007/s40675-017-0065-4. Epub 2017 May 8. PMID: 28553574; PMCID: PMC5427093.